Clinical impact of first‐line PD‐1 or PD‐L1 inhibitors combined with chemotherapy in extensive‐stage small cell lung cancer patients: A real‐world multicenter propensity score‐matched study
Abstract Objectives Our research aimed to evaluate the effectiveness of first‐line immune checkpoint inhibitors (ICIs) with etoposide and platinum (EP) for extensive‐stage small cell lung cancer (ES‐SCLC) and identify prognostic factors, as real‐world outcomes and the inconsistency of PD‐1 and PD‐L1...
Guardat en:
| Autors principals: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2023-05-01
|
| Col·lecció: | Thoracic Cancer |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1111/1759-7714.14874 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|